Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study.
Guillaume MansonAlexandre Thibault Jacques MariaFlorence PoizeauFrançois-Xavier DanlosMarie KostineSolenn BrosseauSandrine AspeslaghPauline Du RusquecMaxime RogerMaud Pallix-GuyotMarc RuivardLéa DoussetLaurianne GrignouDimitri PsimarasJohan PluvyGilles QuéréFranck GradosFanny DuvalFrederic BourdainGwenola MaigneJulie PerrinBenoit GodbertBeatris Irina TaifasAlexandra ForestierAnne-Laure VoisinPatricia Martin-RomanoCapucine BaldiniAurélien MarabelleChristophe MassardJérôme HonnoratOlivier LambotteJean Marie MichotPublished in: Journal for immunotherapy of cancer (2019)
Our results show that PNSs tend to be worsened or revealed by anti-PD-1 or anti-PD-L1 immunotherapy. Cases of paraneoplastic encephalitis are of notable concern, in view of their severity. When initiating immunotherapy, physicians should carefully monitor patients with a pre-existing PNS.
Keyphrases